Literature DB >> 31961195

Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction.

Martin Frydland1, Jacob E Møller1,2, Matias G Lindholm1, Rikke Hansen2, Sebastian Wiberg1, Ole Kristian Lerche Helgestad2, Jakob H Thomsen1, Jens P Goetze3,4, Thomas Engstrøm1,5, Ruth Frikke-Schmidt3,4, Hanne B Ravn6, Lene Holmvang1, Lisette O Jensen2, Jesper Kjaergaard1, Christian Hassager1,7.   

Abstract

BACKGROUND: Cardiogenic shock complicating ST-elevation myocardial infarction is characterised by progressive left ventricular dysfunction causing inflammation and neurohormonal activation. Often, cardiogenic shock develops after hospital admission. Whether inflammation and a neurohormonal activation precede development of clinical cardiogenic shock is unknown. METHODS AND
RESULTS: In 93% of 2247 consecutive patients with suspected ST-elevation myocardial infarction admitted at two tertiary heart centres, admission plasma levels of pro-atrial natriuretic peptide, copeptin, mid-regional pro-adrenomedullin and stimulation-2 were measured on hospital admission. Patients were stratified according to no cardiogenic shock development and cardiogenic shock developed before (early cardiogenic shock) or after (late cardiogenic shock) leaving the catheterization laboratory. In total, 225 (10%) patients developed cardiogenic shock, amongst these patients late cardiogenic shock occurred in 64 (2.9%). All four biomarkers were independently associated with the development of late cardiogenic shock (odds ratio per two-fold increase in risk: 1.19-3.13) even when adjusted for the recently developed Observatoire Régional Breton sur l'Infarctus risk score for prediction of late cardiogenic shock development. Furthermore, pro-atrial natriuretic peptide, copeptin and mid-regional pro-adrenomedullin, but not stimulation-2, added significant predictive information, when added to the Observatoire Régional Breton sur l'Infarctus risk score (area under the receiver-operating characteristic curve, pro-atrial natriuretic peptide: 0.87, p=0.0008; copeptin: 0.86, p<0.05; mid-regional pro-adrenomedullin: 0.88, p=0.006).
CONCLUSIONS: Pro-atrial natriuretic peptide, copeptin, mid-regional pro-adrenomedullin and stimulation-2 admission plasma concentration were associated with late cardiogenic shock development in patients admitted with suspected ST-elevation myocardial infarction. Pro-atrial natriuretic peptide, mid-regional pro-adrenomedullin and copeptin had independent predictive value for late cardiogenic shock development.

Entities:  

Keywords:  ST-elevation myocardial infarction; biomarkers; cardiogenic shock; inflammation; neuroendocrine response

Mesh:

Substances:

Year:  2020        PMID: 31961195     DOI: 10.1177/2048872619896063

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  5 in total

1.  Death-Associated Protein Kinase 1 (DAPK1) Protects against Myocardial Injury Induced by Myocardial Infarction in Rats via Inhibition of Inflammation and Oxidative Stress.

Authors:  Jun Zhang; Jing Zhang; Bo Zhou; Xiaojing Jiang; Yanrong Tang; Zhenzhen Zhang
Journal:  Dis Markers       Date:  2022-01-17       Impact factor: 3.434

2.  High Level of Mid-Regional Proadrenomedullin during ST-Segment Elevation Myocardial Infarction Is an Independent Predictor of Adverse Cardiac Events within 90-Day Follow-Up.

Authors:  Anggoro Budi Hartopo; Ira Puspitawati; Vita Yanti Anggraeni
Journal:  Medicina (Kaunas)       Date:  2022-06-28       Impact factor: 2.948

3.  Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV.

Authors:  Ting Lu; Liao Tan; Kai Xu; Jia Liu; Chong Liu; Guogang Zhang; Ruizheng Shi; Zheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

4.  Hemorrhagic Cerebral Insults and Secondary Takotsubo Syndrome: Findings in a Novel In Vitro Model Using Human Blood Samples.

Authors:  Serge C Thal; Manuel Smetak; Kentaro Hayashi; Carola Y Förster
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

Review 5.  Risk stratification in cardiogenic shock: a focus on the available evidence.

Authors:  C Sciaccaluga; G E Mandoli; N Ghionzoli; F Anselmi; C Sorini Dini; F Righini; F Cesareo; F D'Ascenzi; M Focardi; S Valente; M Cameli
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.